Exton, Pa., Oct. 19, 2011 — Frontage Laboratories, Inc., a global pharmaceutical contract research organization, now offers clients faster clinical trial data collection and increased accuracy through advanced electronic data capture (EDC) technology. Clinical research clients will benefit from a new strategic partnership between Frontage and DSG Inc., a pioneer of EDC solutions for pharmaceutical and biotech companies. Study coordinators working with Frontage Clinical Services worldwide now have access to DSG’s eCaseLink 8.0 EDC software system.
Malvern, Pa., Dec. 13, 2010
The Center for Neuroscience and Regenerative Medicine (CNRM) is using DSG’s eCaseLink™ EDC (electronic data capture) system in three key studies on traumatic brain injury (TBI) in an effort to properly classify, diagnose, and combat one of the leading medical issues for U.S. military troops and veterans.
Malvern, Pa., Feb. 01, 2010
DSG‘s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current Phase II and Phase IIa clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG’s eCaseLink™ to automate and manage the data collection process during the clinical trial life cycle. In addition, DSG combines data management services with eCaseLink™ to seamlessly optimize data collection and analysis. The result is clean clinical trial data, collected and analyzed efficiently. This accelerates the clinical trial process, helping to safely speed these treatments to those who need them.
Malvern, Pa., Jan. 11, 2010
DSG, a leader in electronic data capture (EDC) has teamed up with a leading-edge pharmaceutical company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes. The focus is on developing molecular imaging products that are leading the way to the early detection of human diseases. DSG’s eCaseLink™ EDC (Electronic Data Capture) supports three current clinical trials for Alzheimer’s disease, Parkinson’s disease and Diabetes. eCaseLink™ supplies real-time capability to review case documents and metrics across all study sites, significantly increasing clinical trial management speed, while reducing study management costs by as much as 30 percent.
October, 2009
A clear and present danger has emerged for the pharmaceutical and medical device industry that threatens its very core. After a wave of criticism about the way federal drug regulators are performing their duty, a Supreme Court majority handed down a decisive endorsement of lawsuits in state courts to address deficiencies at the national level.
100% EDC, A Necessity. From “Is 100% EDC Realistic?” presented by Suzanne Lamerand of DSG, Inc. at the 2009 SCDM Annual Conference, 2009.
October 14, 2009
The pharmaceutical and device industry faces a hostile litigious and regulatory environment. This current climate can stifle research and, as a result, impede progress that could improve the health care of all Americans. The concern is over a new level of scrutiny aimed at pharmaceutical and medical device companies. The good news is that the industry can employ existing technologies to head off potential problems and dramatically reduce risk. That technology is EDC.
50 Years is a long time to wait for a Drug
By Lisa Henderson | Published: October 6, 2009
Lupus, a chronic, severe autoimmune disease that effects 1.5 million Americans, primarily women in their childbearing years, can lead to kidney failure, heart attack, atherosclerosis or death. According to a report issued yesterday by the Lewin Group, a health care consulting firm, lupus stands apart from other chronic autoimmune diseases because the majority of therapies currently used to effectively manage lupus have not been approved by the FDA for the disease. Many of these medications often have side effects that can be worse than the primary disease, including osteoporosis, weight gain, high blood pressure, diabetes, sterility, liver damage, and the increased risk of infection. There has been no new drug approval for lupus in more than 50 years, since the Eisenhower Administration.
DSG in the spotlight at 2009 SCDM Annual Conference
October 01, 2009
DSG's EDC technology presence at 2009 SCDM conference highly anticipated - MALVERN, Pa.--(Business Wire)-- DSG, Inc., the leader in EDC and clinical software technology, is already the center of attention leading up to the 2009 SCDM Annual Conference. The excitement is centered around DSG`s continuing role as a pioneer in the EDC(electronic data capture) field, with over 500 attendees eager to see the latest developments and the future of EDC from DSG.
Cipher uses DSG`s EDC in effort to give hope to severe acne sufferers
September 14, 2009
Cipher Pharmaceuticals conducts Phase 3 trial study for new severe acne treatment- MALVERN, Pa.-- DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX:DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG`s eCaseLink for its Phase 3 dermatology study on its new compound for the treatment of severe acne. Cipher`s new treatment offers new hope for patients with severe inflammatory or recalcitrant nodular acne who are unresponsive to conventional therapy.
DSG’s Successes with Human Genome Sciences
By Lisa Henderson | Published: September 2, 2009
In covering clinical trials, we are seeing more focus on the activities in specific therapeutic areas. Not that they didn’t exist before, but the frequency with which companies are identifying the specific conditions for which they have experience are on an uptick. These experiences can parlay into other contracts in similar conditions, or add to the company’s cadre of experience, as well as the overall impression, the company already exhibits.
Human Genome Sciences achieves Lupus drug goals with DSG`s EDC
August 17, 2009
Human Genome Sciences announced that BENLYSTA met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). These results show that BENLYSTA has the potential to become the first new approved drug in decades giving hope to people living with systemic lupus.
DSG supports HGS on four global Phase 3 studies concurrently, providing data capture and supporting data management through its function rich eCaseLink EDC software. The study included nearly 400 electronic case report forms per subject, which were highly complex in design and had nearly 1,200 edits per screen. DSG provided critical data reporting tools based on study requirements, allowing HGS data management personnel to continually monitor and efficiently insure data quality.
DSG announces record growth for first half of 2009
June 22, 2009
DSG Inc., the industry leader in electronic data capture (EDC) for clinical trial data collection and management, today announced, from the 45th Annual Meeting of the Drug Information Association, its continued record growth and profitability for the first half of 2009.
Re-branding, EDC, and swag … oh my!
April 29, 2009
Speaking of EDC: I chatted briefly with Tony Varano, who founded e-clinical vendor DSG 17 years ago. His company deployed its first EDC study in 1998, which was then used in a clinical trial in early 2000. In April 2008, DSG established a wholly owned subsidiary in India. Being a longtime provider of EDC services, I asked Mr. Varano if electronic studies are finally poised to supplant traditional paper-based trials as the data management standard.“Why it’s been too slow to adopt is all about money,” Mr. Varano says. “All these business have been set up to process the paper. There’s been a reluctance over a long period of time because there’s a lot of businesses out there that depended on that type of processing of studies.